Illumina (NASDAQ:ILMN) CAO Sells $80,000.00 in Stock

Illumina, Inc. (NASDAQ:ILMN) CAO Scott Ericksen sold 500 shares of Illumina stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $160.00, for a total transaction of $80,000.00. Following the transaction, the chief accounting officer directly owned 14,446 shares of the company’s stock, valued at approximately $2,311,360. This trade represents a 3.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Illumina Stock Up 5.2%

Shares of NASDAQ:ILMN opened at $170.93 on Thursday. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.56. The stock has a fifty day simple moving average of $136.19 and a two-hundred day simple moving average of $133.03. Illumina, Inc. has a 12-month low of $81.75 and a 12-month high of $172.49. The stock has a market capitalization of $25.86 billion, a price-to-earnings ratio of 31.08, a PEG ratio of 2.69 and a beta of 1.50.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.05 by $0.10. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The firm had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same quarter in the prior year, the firm posted $0.97 earnings per share. The business’s revenue was up 4.8% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. On average, research analysts anticipate that Illumina, Inc. will post 5.2 earnings per share for the current fiscal year.

More Illumina News

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Guggenheim raised its price target on Illumina to $180 from $170 and reiterated a Buy rating, reflecting optimism about clinical sequencing momentum, consumables pricing, and the company’s pipeline. Article
• Positive Sentiment: Integrated DNA Technologies expanded its collaboration with Illumina, linking xGen FFPE and cfDNA workflows to DRAGEN and Connected Insights, which could deepen Illumina’s role in oncology research and support software adoption. Article
• Positive Sentiment: Recent commentary highlighted Illumina’s better execution, stronger NovaSeq X adoption, and higher full-year 2026 guidance, which has helped extend the stock’s rally. Article
• Neutral Sentiment: Illumina reported small insider sales, including a routine Rule 10b5-1 sale by the chief accounting officer, which is not unusual but adds to scrutiny around insider activity. SEC filing
• Negative Sentiment: Director Keith A. Meister sold a large block of shares in multiple transactions, which could weigh on sentiment despite no direct sign of operational weakness. SEC filing

Analyst Ratings Changes

ILMN has been the subject of several research analyst reports. Royal Bank Of Canada initiated coverage on Illumina in a report on Thursday, May 14th. They issued an “outperform” rating and a $170.00 price objective for the company. Citigroup boosted their price objective on shares of Illumina from $80.00 to $95.00 and gave the company a “sell” rating in a report on Monday, May 4th. JPMorgan Chase & Co. raised their target price on shares of Illumina from $120.00 to $125.00 and gave the stock a “neutral” rating in a report on Friday, May 1st. Wall Street Zen lowered shares of Illumina from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Finally, Piper Sandler dropped their price target on Illumina from $195.00 to $170.00 and set an “overweight” rating on the stock in a research note on Monday, February 9th. Seven research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, Illumina presently has an average rating of “Hold” and a consensus price target of $138.38.

Institutional Trading of Illumina

Several hedge funds have recently bought and sold shares of the stock. Elyxium Wealth LLC bought a new position in shares of Illumina in the fourth quarter worth about $25,000. Board of the Pension Protection Fund bought a new stake in Illumina during the 4th quarter worth approximately $26,000. Creative Capital Management Investments LLC lifted its holdings in Illumina by 160.0% during the fourth quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock valued at $26,000 after purchasing an additional 120 shares in the last quarter. TD Waterhouse Canada Inc. bought a new position in shares of Illumina in the fourth quarter worth approximately $26,000. Finally, Laurel Wealth Advisors LLC bought a new position in shares of Illumina in the fourth quarter worth approximately $26,000. Institutional investors own 89.42% of the company’s stock.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.